
Stimulating insulin secretion from the pancreas when blood glucose rises
Inhibiting glucagon release, which helps prevent excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists help bring blood sugar down by encouraging insulin secretion and limiting the liver’s production of glucose. These drugs are often prescribed in combination with or after oral agents like metformin when those treatments do not sufficiently control diabetes. Some GLP-1 agonists have the added benefit of lowering the chance of heart attacks, strokes, or other cardiac events in individuals who have type 2 diabetes along with established heart disease.
In people without diabetes, GLP-1 agonist medications such as Wegovy and Saxenda have gained FDA approval as effective tools for weight loss. They act by enhancing satiety and reducing hunger, which supports lower calorie intake without constant feelings of hunger. Clinical data show that using these drugs together with diet and exercise changes often leads to meaningful and sustained weight loss.
GLP-1 receptor agonists act on blood sugar by increasing insulin secretion when you eat and reducing glucagon, which normally raises glucose. This combination keeps post meal blood sugar from rising too quickly and strengthens overall glycemic control. As their effect depends on current glucose levels, they pose a lower risk of hypoglycemia than many traditional medications.
A standout benefit of GLP-1 therapy is its effectiveness in supporting sustainable weight loss and long term weight management. These medications slow the movement of food from the stomach and activate brain receptors related to satiety, which reduces hunger and helps people comfortably consume fewer calories. Clinical research on liraglutide, semaglutide, and tirzepatide shows that they can drive notable and lasting weight loss when they are used alongside changes in diet and physical activity.



GLP-1/GIP co-agonists act on both GLP-1 and GIP receptors to amplify insulin release and improve satiety beyond what is seen with GLP-1 alone. This combined incretin action helps lower blood sugar more efficiently and reduces appetite, positioning these drugs as next generation options for diabetes and obesity management.
GLP-1/glucagon co-agonists target GLP-1 and glucagon receptors in tandem, increasing fat burning and supporting weight loss while helping individuals retain lean muscle mass.

